The SELECT Trial: What Wegovy's Heart-Disease Evidence Means for You

What the SELECT trial actually tested, and who was in it

The SELECT trial was a randomised, double-blind, placebo-controlled study that ran across multiple countries and followed 17,604 adults for a median of around 3.3 years. Every participant had a BMI of 27 or above and confirmed cardiovascular disease (meaning a prior heart attack, stroke, or peripheral arterial disease) but crucially, none had type 2 diabetes. That distinction matters enormously, because earlier cardiovascular benefits seen with semaglutide in the SUSTAIN-6 trial were in a diabetic population, where glucose-lowering itself confounds the picture. SELECT isolated the cardiovascular effect in people whose sole metabolic issue was excess weight.

The primary outcome was a composite of three events: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Over the trial period, 6.5% of participants in the semaglutide group experienced one of these events compared with 8.0% in the placebo group, a 20% relative risk reduction. Results from the SELECT study are examined in detail on our SELECT study overview page, including the breakdown by individual endpoint. The numbers are, by the standards of cardiovascular medicine, striking.

One detail that surprises people: weight loss in the semaglutide group averaged around 9% of body weight over the trial period. The cardiovascular benefit appeared earlier than that weight curve would predict, which prompted researchers to investigate whether semaglutide's anti-inflammatory, blood-pressure-lowering, and lipid-modifying effects contribute independently of the kilograms lost. No firm consensus exists yet, but the question is driving a generation of follow-on research.

The specific decision this evidence puts in front of you

If you have obesity or overweight alongside established heart disease, SELECT's findings are directly relevant, but they do not translate into a simple recommendation. The trial population had pre-existing, diagnosed cardiovascular disease. If your situation is different (higher BMI, active weight-management goal, no prior cardiac event), the evidence base you should be weighing is the STEP programme rather than SELECT. A question our prescribers hear most weeks is: "I read about Wegovy and heart attacks, does that mean it's good for my heart?" The honest answer is that SELECT gives strong evidence of benefit in a specific population, and whether you fit that population is a clinical judgement.

For weight management specifically, Wegovy's UK weight-management licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. The cardiovascular risk-reduction licence is separate and has its own eligibility criteria, your prescriber will assess which applies. If you want to understand the weight-related conditions that typically qualify someone for treatment, our guide to weight-related comorbidities and Wegovy covers them clearly.

The SELECT trial was also notable for what it did not show: the 20% relative risk reduction was consistent across subgroups defined by age, sex, BMI category and region, but the absolute risk reduction varied. People with higher baseline cardiovascular risk saw a larger absolute benefit. That is the kind of individualised calculation a prescriber runs through, not something a headline figure can do for you.

What SELECT does not tell you about starting semaglutide

SELECT answers a specific epidemiological question. It does not tell you how you will respond to semaglutide, whether the dose will suit you, or how to manage the side effects that affected a meaningful proportion of participants. Gastrointestinal effects (nausea, loose stools, vomiting, and reflux) were more common in the semaglutide group and led to a higher discontinuation rate than placebo. These typically ease as the body adjusts, particularly with the gradual titration schedule: doses step up approximately every four weeks, starting at 0.25mg, through 0.5mg, 1.0mg, and 1.7mg before reaching the 2.4mg maintenance dose used in SELECT. More information on how semaglutide works and what to expect is on our semaglutide information page.

The MHRA requires that any suspected side effects be reported via the Yellow Card scheme, this ongoing pharmacovigilance is how post-market safety is monitored beyond what trial conditions can capture. That matters particularly because Wegovy carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring. The NHS also publishes patient-level guidance on semaglutide covering common side effects, missed doses and storage, worth reading before you start.

The cardiovascular benefit in SELECT is real and peer-reviewed. It is not a reason to start treatment without assessment, and it is not a guarantee of the same outcome for any individual. Those two things can both be true.

Accessing Wegovy through a private prescription after SELECT

SELECT's publication in late 2023 accelerated MHRA approval of the cardiovascular-risk-reduction indication for Wegovy in the UK, which sits alongside the existing weight-management licence. NHS access remains limited: NICE's recommendation for semaglutide (TA875) restricts NHS prescribing to specialist weight management services, with specific BMI thresholds and a maximum treatment duration of two years. Waiting times through NHS pathways can be long, and not everyone meets the current commissioning criteria.

For people who want to explore private treatment, the regulated route is a prescription from a GPhC-registered pharmacy following a proper clinical assessment. You can learn what the process of getting Wegovy through a private UK pharmacy looks like, or read about the wider Wegovy trial programme to understand the evidence base more fully. If you are weighing up whether semaglutide or another treatment suits your situation, our free consultation is reviewed the same day by a GPhC-registered Independent Prescriber. Check your eligibility there, a real clinician reads your answers, not an automated filter.